BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PKN605 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of PKN605\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07797322-11267@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:PKN605: Phase 1 readout est. (NCT07797322)
DESCRIPTION:PKN605\, phase 1.\nStudy: A Study to Investigate the Pharmacoki
 netics and Safety of PKN605 in Participants With Moderate and Severe Renal
  Impairment Compared to Matched Control Subjects With Normal Renal Functio
 n\nEstimated primary completion: 1 March 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pkn605#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07797322
URL:https://assetmemo.bio/drug/pkn605#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217067-11267@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270909
DTEND;VALUE=DATE:20270910
SUMMARY:PKN605: Phase 2 readout est. (NCT07217067)
DESCRIPTION:PKN605\, phase 2\, Atrial Fibrillation.\nStudy: A Study to Inve
 stigate the Efficacy\, Safety\, Tolerability and Pharmacokinetics of PKN60
 5 in Participants With Atrial Fibrillation\nEstimated primary completion: 
 9 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pkn
 605#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07217067
URL:https://assetmemo.bio/drug/pkn605#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
